The Market's Junk Drawer: AI Grifters, Nuclear Leverage, and SPACs Refusing to DieGlobal Report·Aug 18 at 05:12 AMBRNX+16.56%GPUS.CLSB
Cerenome | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 411 KEarnings Watch·Aug 15 at 12:41 AMCNSY+2.33%
Cerenome Reports Second Quarter 2026 Financial Results and Business UpdateUnusual Whales·Aug 14 at 03:17 PMPSTV0.00%CNSY+2.33%
Plus Therapeutics Q2 FY26 net loss widens to $9.01 million; operating loss widens to $9.06 millionPUBT·Aug 14 at 03:16 PMCNSY+2.33%PSTV0.00%
Capital Rotation Beyond Mega-Caps: Institutional Flows Target Supply Chains and Sports FranchisesGlobal Report·Aug 5 at 04:13 AMFUBO-3.40%CNSY+2.33%
Plus Therapeutics amends bylaws to reflect corporate name change to CerenomePUBT·Aug 4 at 04:34 PMPSTV0.00%CNSY+2.33%
Plus Therapeutics to trade on Nasdaq as Cerenome under CNSY ticker from Aug. 3PUBT·Jul 31 at 07:32 AMPSTV0.00%CNSY+2.33%
Cerenome Launches as an Integrated CNS Oncology Company | PSTV Stock NewsStockTitan·Jul 30 at 11:30 PMPSTV0.00%CNSY+2.33%
Plus Therapeutics signs Medical Mutual coverage deal for CNSide CSF tumor cell assay in Ohio, KentuckyPUBT·Jul 21 at 06:30 AMPSTV0.00%CNSY+2.33%
Plus Therapeutics partners with Genomic Testing Cooperative to add NGS to CNSide CSF assay platformPUBT·Jul 16 at 06:31 AMPSTV0.00%CNSY+2.33%
From Buybacks to Insider Buying: U.S. Mid-Caps Signal Capital ShiftGlobal Report·Jul 14 at 06:47 AMBDX+2.33%AB+0.67%
Plus Therapeutics flags availability of CNS cancers guidelines update releasePUBT·Jul 14 at 06:31 AMPSTV0.00%CNSY+2.33%
Plus Tx rebrands as Cerenome as it deepens AI strategyFiercepharma·Jul 1 at 06:26 AMPSTV0.00%CNSY+2.33%
